RBC Capital Reiterates Outperform on Biogen, Maintains $292 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams has reiterated an 'Outperform' rating for Biogen (NASDAQ:BIIB) and maintained a price target of $292.
September 19, 2024 | 1:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has reiterated its 'Outperform' rating for Biogen, maintaining a price target of $292, indicating confidence in the company's performance.
The reiteration of an 'Outperform' rating and a maintained price target of $292 by RBC Capital suggests positive sentiment and confidence in Biogen's future performance, likely leading to a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100